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A B S T R A C T
The estrogen receptor (ER) is a ligand inducible transcription factor that regulates a large
number of target genes. These targets are particularly relevant in breast cancer, where
the sensitivity of the tumor to estrogens determines whether the patients can be treated
with endocrine therapy such as tamoxifen. Identifying genomic ER targets is a daunting
task. Quantifying expression levels of suspected target genes after estradiol stimulation
or, more recently, using expression microarrays to this effect will reveal which genes are
regulated by estradiol, however, without discriminating between direct and indirect tar-
gets. The identification of the palindromic sequence that defines the estrogen responsive
element (ERE) allows for the in silico discovery of putative ER targets in the genome. How-
ever the ER can also bind imperfect EREs and half sites, and can bind indirectly via other
factors. Chromatin immunoprecipitation (ChIP) can yield all ER genomic target sites. Cou-
pling of ChIP with genome-wide tiling arrays allows for the genome-wide unbiased identi-
fication of direct ER target sequences.
ª 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
1. Introduction
In 1896 Beatson observed that removing the ovaries could lead
to remission of breast cancer (Beatson, 1896). Although at that
time hormoneswere not yet discovered, his experimentswere
the first to connect estrogens with breast cancer. More than
60 years later it was demonstrated that estrogens were
retained in target tissues (Jensen and Jacobson, 1962), laying
the foundation for the subsequent identification of steroid
receptors. Indeed, in 1968 O’Malley described that changes
in gene expression occurred after estrogen stimulation, indi-
cating estrogen receptor (ER) functions as a transcription fac-
tor (O’Malley et al., 1968). Soon after, a protein that specifically
bound estrogens was found in breast tumors, and its quantity
could predict the response of these tumors to endocrine dis-
ruption (Jensen et al., 1971; McGuire, 1973). With the cloning
of the ER in 1986 (Green et al., 1986; Greene et al., 1986) and
subsequent identification of its functional domains the role
for the ER as a ligand dependent transcription factor became
apparent (Green et al., 1986; Greene et al., 1986; Kumar et al.,
1987).
The ER is a member of the superfamily of nuclear recep-
tors, which are structurally related ligand-inducible transcrip-
tion factors, including steroid receptors (SRs), thyroid/
retinoids receptors (TR, RARs and RXRs), vitamin D receptors
(VDR), LXR, PPARs, and orphan receptors for which no ligand
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has been yet identified. After binding of estrogen to the
estrogen-binding site on the ER, the receptor dimerizes, trans-
locates to the nucleus of the target cell, and binds to specific
regions on chromatin, the so-called estrogen response
elements (EREs). In addition, the ER can interact with other
transcription factors, SP-1, AP-1 and NF-kB bound to their
regulatory regions. These interactions, and the specific genes
that are regulated by the interaction of the ER with chromatin
regions have been subject to research over the years. This re-
view will focus on the methods and research done to identify
ER targets genes.
2. Expression
Elucidating ER target genes has for long been done on a
gene-by-gene basis, measuring the effect of estrogen stimula-
tion on the expression of a single gene. By differentially
screening cDNA libraries of induced and non-induced cells
several target genes have been discovered, e.g. pS2/TFF1
(Brown et al., 1984; Jakowlew et al., 1984). Recently, investiga-
tion of global expression changes upon estradiol induction by
SAGE or microarray has identified many ER target genes
(Charpentier et al., 2000; Cunliffe et al., 2003; Frasor et al.,
2003; Inoue et al., 2002; Seth et al., 2002). Interestingly, these
global expression experiments indicated that around half of
ER target genes are down regulated upon inductionwith estro-
gen. Many of the down-regulated genes are known to inhibit
the cell cycle, are pro-apoptotic or are cytokines and growth
factors that inhibit proliferation. This is in agreement with
the view that estrogen promotes cell survival by down regulat-
ing pro-apoptotic genes. Although global expression profiling
provides a wealth of information on estrogen induced gene
expression, it cannot distinguish between direct and indirect
ER targets, i.e. genes that are regulated by other genes that
are directly regulated by the ER. For this, protein synthesis
inhibitors cycloheximide or puromycin can be used, although
unspecific effects of these drugs cannot be excluded. All tar-
gets that are regulated by estrogens in the presence of protein
synthesis inhibitors should be bona fide direct ER targets. Sou-
lez and Parker used this to confirm that the P450-IIB enzyme
was a direct target for the ER in ZR75-1 cells (Soulez and
Parker, 2001), andWang et al. (2004) found EEIG1 to be a direct
ER target in MCF7 cells. To the best of our knowledge, no ge-
nome-wide expression profile has been performed in breast
cancer cells in the presence of protein synthesis inhibitors.
3. ERE
Klein-Hitpass et al. (1986) identified an estrogen response
element in the Xenopus vittelogenin A2 gene in 1986. They
showed that this element functions in humans and defined
a palindromic sequence (50-GGTCACAGTGACC-30) as the core
ERE (Klein-Hitpass et al., 1986). With the sequencing of the
human genome it became possible to search in silico for the
presence of EREs. These computational approaches have
been used to identify ER target genes with limited success.
From an extensive study where 71,119 EREs were identified,
only 3 were perfect ERE palindromes (Bourdeau et al., 2004).
By narrowing down to promoter regions still 12,515 EREs were
identified and by including conservation with mouse, 660
EREs remained of which several could be validated. Other au-
thors have used similar approaches (Kamalakaran et al.,
2005). As the ER can bind imperfect EREs and half sites, it is
computationally very difficult to distinguish between real
binding sites and noise. In addition, ER can bind indirectly via
other factors, which cannot be assessed using this approach.
4. ChIP
Chromatin immunoprecipitation (ChIP) is a new and very
powerful technique by which transcription factor/co-factor
occupancy of a given locus can be determined in its chromatin
context in vivo. In brief, protein and DNA are cross-linked in
the living cell using formaldehyde, chromatin is fragmented,
and the transcription (co)factor of interest is immunoprecipi-
tated with specific antibodies. The relative amount of a partic-
ular DNA fragment cross-linked to the transcription factor
(and therefore present in the precipitate) can be determined
by real-time quantitative PCR, and is a measure of the occu-
pancy of the factor at that particular position in the genome
(Figure 1). Such ChIP approaches provide valuable information
about the involvement and temporal order of transcription
factor and co-factor recruitment during activation or repres-
sion of a gene or locus. Furthermore, ChIP provides a means
to accurately determine the epigenetic status of the locus.
First ChIP experiments directed at the ER focused on a lim-
ited number of known binding sites and investigated binding
of ER and cofactors. For example, Shang et al. (2000) found that
the ER and a number of coactivators rapidly associate with
chromatin at the c-Myc, pS2 and CATD estrogen responsive
promoters following estrogen treatment in a cyclic fashion.
More recently, a high throughput ChIP approach, ChIP cloning,
was described by Laganiere et al. (2005a). Here, the co-precip-
itated DNA fragments were cloned and subsequently se-
quenced. This enabled the identification of unknown ER
binding sites without any bias towards annotated genes and
promoter regions. A disadvantage of this method is that large
scale sequencing facility is needed and that it is difficult to
discriminate between true binding sites and background
DNA resulting in the necessity to do many work intensive
validations.
Recently, ChIP has been coupled to microarray experi-
ments, enabling the unbiased identification of ER binding sites
on a genome wide scale (Figure 1). Initially, promoter arrays
were used, specifically containing upstream regions from
known genes as the size of the genome made it impossible
to completely cover it sequence. These arrays are obviously
biased and will miss a large number of binding sites as recent
data shows that many transcription factors also bind in inter-
genic regions, introns and downstream of known genes. De-
spite this, this approach has been used with some success.
Laganiere et al. identified 153 promoters bound by ER in the
presence of estradiol (Laganiere et al., 2005b). Cheng used
a promoter/CpG island array to identify ER binding, H3K9 acet-
ylation and H3K9 dimethylation at different time points.
Ninety-two ER responsive promoters were identified, and
a coregulatory role for c-myc at a subset of promoters was
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demonstrated. In addition, the physical interaction between
ER and c-myc via the bridging factor TRRAPwas shown (Cheng
et al., 2006). Recently, a study using a ChIP-promoter array
variant, i.e. ChIP coupled to a DNA selection and ligation
(DSL) strategy full genome promoter array, found 578 high
confidence promoter ER gene targets in MCF-7 cells (Kwon
et al., 2007). In unsupervised clustering analyses, they found
that the 54 genes that were regulated by estradiol and that
were directly regulated by the estrogen receptor as discovered
by ChIP-DSL promoter array could identify a subset of patients
with ER negative tumors, of higher grade and with a much
poorer prognosis then the other patients.
By combining ChIP with genome wide tiling arrays (ChIP-
chip), ER binding can be investigated in a truly unbiased
fashion. Tackling mammalian genomes is exceedingly more
difficult and challenging due to its shear size, the presence
of over 30,000 protein-coding genes sprinkled into a bed of
highly repetitive sequences. In mammals, the identification
of transcription factor binding sites using bioinformatic tools
is complicated because regulatory regions are much wider
spread than in yeast and can be located as far as hundreds
of kb upstream or downstream or within the transcribed re-
gion. Indeed, by using Affymetrix tiling arrays spanning chro-
mosome 21 and 22, 57 ER binding sites were identified of
which the majority was located distal from genes and not in
promoter regions (Carroll et al., 2005). Comparing these data
with a polymerase (pol) II ChIP-chip showed the presence of
pol II at the ER binding sites. Sequence analysis of the ER bind-
ing sites showed that these were enriched with a Forkhead
motif. FoxA1/HNF3alpha expression correlates with the pres-
ence of ER in breast tumors and cell lines (van ’t Veer et al.,
2002; Lacroix and Leclercq, 2004). By ChIP-qPCR Carroll
showed that in the absence of estradiol FoxA1 was present
for most targets and dissociated upon ligand induction
(Carroll et al., 2005). They postulate a role for FoxA1 as a pio-
neering factor whereby FoxA1 is present on the chromatin
and facilitates the interaction of the ER with its binding site.
Recently, Carroll published a genome wide ChIP-chip for
the estrogen receptor and RNA pol II, identifying 3665 high
confidence ER binding sites and 3629 RNA pol II binding sites
(Carroll et al., 2006). As described earlier for chromosome 21
and 22, mapping the location of the binding sites to nearby
genes shows that only 4% is located within 1 kb upstream of
a gene. Analysis of ER binding sites for enriched DNA
sequences identified ERE, Forkhead, AP-1, Oct and C/EBP
motifs. Pair wise analysis showed that the ERE and AP-1 motif
occur exclusively. The Oct, Forkhead, and C/EBP motifs have
a positive correlation. Further investigation showed a role
for the coregulator NRIP in ER induced repression of target
genes. NRIP is a target of the ER and can interact with ER
AP-1 complexes to repress expression of target genes.
5. Amplification methods
For hybridizing ChIPed DNA micrograms of DNA are needed,
while ChIP experiment yields are in the nanogram range. An
amplification step is needed to obtain sufficient material.
The majority of studies so far used LM-PCR as their amplifica-
tionmethod. Here, oligos are ligated to the ChIPedDNA,which
are used as primer sites for a subsequent PCR reaction. This
yields enoughmaterial for ChIP-chip. The efficiency of LM am-
plification is unfortunately biased towards GC regions. This
bias is partially compensated for by the fact that it is present
Figure 1 – Overview of ChIP-chip. (A) Using formaldehyde protein–
protein and protein–DNA are cross-linked in vivo. The cross-linked
chromatin is subsequently isolated. (B) The isolated chromatin is
sheared in smaller fragments by sonication yielding fragments of 500–
1000 bp. The protein or histone modification of interest is
precipitated using an antibody. The cross-linked DNA is co-
precipitated. (C) The unbound chromatin is washed away. (D) The
cross-linking is reversed and the DNA is isolated. The DNA is
amplified by either LM-PCR or T7 linear amplification of DNA. (E)
Total genomic DNA and ChIP DNA are differently labeled with Cy3
and Cy5. (F) Labeled DNA is hybridized on promoter arrays or arrays
spanning the total non-repetitive genome.
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both in the input aswell as in the ChIP sample, so the ratiowill
be constant. Nevertheless this bias can cause false positives. A
linearmethod of amplifying DNA is TLAD (T7 linear amplifica-
tion of DNA) (Liu et al., 2003). In short, a T7 promoter is incor-
porated at the end of the ChIPed DNA fragments. For this the
ChIPed DNA is tailed using a terminal transferase tailing step.
A T7 promoter is then annealed to the DNA after which a sec-
ond strand is synthesized to fill the DNA fragments. This is
used as a template for an in vitro transcription reaction. The
RNA produced is subsequently reverse transcribed to DNA.
This linear amplification method has no bias towards CG con-
tent and preserves sample complexity.
6. Identifying ChIP sequences
There are several methods to determine the amount and se-
quence of ChIPed DNA fragments and their ChIP/input ratio.
The most sensitive way is by qPCR, although this can only
be used for a relative small number of sites and sequence
information is necessary to develop primers, so no new sites
can be identified. For qPCR, one needs to know the targets,
only a few targets can be measured at the same time, but on
the other hand, qPCR exhibits high sensitivity, there is no
preamplification step required, and it is still the gold standard.
By cloning the ChIP fragments (ChIP cloning) and sequencing
all clones (Laganiere et al., 2005a), all information is unbiased,
many targets are assessed at a time, the technique has a high
sensitivity, but distinguishing real targets from background
can be problematic. To identify a large number of binding sites
microarrays (ChIP-chip) can be used. These can contain up to
4.6million probes and this number is increasing as technology
develops further. Several types of arrays exist; promoter ar-
rays contain promoter regions of known genes. All promoter
regions can be spotted on one array,making it very affordable.
Promoter arrays cover only a small portion of the whole
genome, and recent studies show that the majority of ERs
(Carroll et al., 2005, 2006) bind to non-promoter regions. Pro-
moter arrays hence show a limited view of transcription factor
binding and will miss a large part of enhancers and non-
annotated transcripts. With the ChIP-DSL (DNA selection
and ligation) technique a promoter array is also used (Kwon
et al., 2007). Each promoter is covered by one 40 bp probe
and for each probe there is a matching primer set of two
20 bp primers. The ChIPed fragments are biotinylated and
attached to a carrier. Unbound fragment are washed away
and the primer pairs that contain the promoter specific
sequence and a T7 or T3 sequence are hybridized to the frag-
ments. Two matching primer pairs are then ligated allowing
the amplification of the product by using T7 and T3 primers.
With thismethod only fragments that are present on the array
are amplified. The authors claim increased sensitivity and are
able to use a small number of cells (Kwon et al., 2007). ChIP-
DSL has the same drawbacks as other promoter arrays,
namely a very biased selection of binding sites. In addition,
each promoter is covered with only one probe. The specific
amplification of only fragments that are present on the array
and the fact that the method can tolerate incomplete cross-
linking makes this a sensitive method. Using chromosome
wide arrays, all binding site regions can be identified
throughout a complete chromosome. An extension of chro-
mosome wide array is the genome wide array set (currently
38 slides for Nimblegen or 14 slides for Affymetrix), which
covers the whole genome at high resolution. Array synthesis
and scanning is still developing fast, enabling more and
more probes per array. Because of this development genome
wide arrays will become cheaper and the use of promoter
and chromosome wide arrays will decline.
7. Enhancer/promoter interactions
Recent data showed that ER binding sites could be located far
from any gene (Carroll et al., 2005, 2006). They tested the
hypothesis that these distal sites play a role during transcrip-
tion of distal genes. To test this enhancer/promoter interac-
tion chromosome conformation capture (3C) is used (Dekker
et al., 2002; Horike et al., 2005). In short, proteins and DNA
are cross-linked using formaldehyde, sheared in small frag-
ments and a chromatin immunoprecipitation is carried out
using a specific antibody. The fragments are subsequently
digested with a restriction enzyme and ligated. If two DNA
fragments are in close vicinity because of promoter enhancer
interaction they will be ligated to each other. By quantitative
PCR using primers that span this ligation the enhancer pro-
moter interaction can be determined. Recently this technique
has been adapted for high throughput using microarrays,
enabling the screening of promoter enhancer interactions on
a large scale (Zhao et al., 2006). Identification of promoter
enchancer interactions is an important step to obtain more
biological information from ChIP-chip data. The vast amount
of data obtained by genome wide ChIP-chip needs to be dis-
tilled into meaningful biological data. This is the next step
and bottleneck of genome wide transcription factor profiling.
8. Clinical significance and future directions
What can we learn from knowledge of the profile of direct
estrogen receptor gene targets? On a fundamental level, these
experiments help expanding our understanding of how gene
transcriptomes interact. Clinically, understanding of the func-
tioning of the ER is still important in breast cancer, more than
110 years after Beatson (1896). So far all prognostic expression
array studies in breast cancer have found the ER status to be
the most pronounced independent factor that dichotomizes
patients after unsupervised clustering of expression profiles
of their primary tumors (van ’t Veer et al., 2002; Sorlie et al.,
2001). Amplification of the ER gene has recently been de-
scribed as a common early event in a large subset of breast
cancers (Holst et al., 2007). ER status dependent expression
profiles are being identified (Abba et al., 2005), and ER regu-
lated gene expression profiles are used to predict survival in
breast cancer patients (Oh et al., 2006). Thus, for the clinical
evaluation of breast tumors, the ER is still crucial. The ER pos-
itive patients can be subdivided into so-called luminal A and
luminal B type tumors based on their gene expression profile
(Sorlie et al., 2001), with the latter group having a relatively
poor prognosis. Differences in functioning of the ER in these
two patient subgroups will help elucidating the mechanisms
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involved in determining the prognosis of breast cancer pa-
tients. Furthermore, interest is now changing from defining
patients with a poor prognosis (i.e. disease outcome irrespec-
tive of or in the absence of treatment) to identifying predictive
gene profiles for, e.g. tamoxifen resistance (Jansen et al., 2005).
Tamoxifen has been the gold standard for the endocrine treat-
ment of patients with ER positive breast cancers for over
25 years (Jordan, 2003). Differences in direct gene targets of
the ER in the presence of agonists (estradiol) or antagonists
(tamoxifen) might be relevant for identifying mechanisms
involved in (in)sensitivity to tamoxifen or other ER antagonists
(Jordan, 2004). With knowledge of the genome-wide DNA
binding sites of ER alpha, the effects of coregulators, ER beta
or growth factors (Shou et al., 2004; Chang et al., 2006; Girault
et al., 2006) on ER alpha interaction profiles can now be
studied, which have relevance for revealing the mechanisms
involved in tamoxifen resistance.
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